AI readiness is not digital maturity. It is governing capability.
The next NHS bottleneck will not be technology. It will be whether the Board can govern what arrives.
AI is moving from trial into operation.
Ambient voice. Automated documentation. Workflow tools. Decision support. Predictive models. The question is no longer whether AI will arrive. The question is whether the organisation can govern it.
PRAXIA.CH works with NHS Boards, executive teams, and assurance committees to evidence AI readiness before adoption outruns the assurance behind it.
The next question for Boards is not whether AI will arrive. The question is whether the organisation is ready to govern AI safely, lawfully, and defensibly.
The mandate is being drawn now.
The National Commission into the Regulation of AI in Healthcare is advising the MHRA on a new framework, due in 2026. Post-market surveillance. The roles of developers, providers, and professionals. Liability across the adoption cycle.
HSJ reports that an AI readiness test for healthcare providers is under consideration. The direction is plain. NHS organisations will need to evidence not only that an AI product is safe, but that the organisation has the systems, infrastructure, governance, and capability to use it safely.
That is PRAXIA’s field.
Six questions a Board must be able to answer.
PRAXIA helps NHS Boards seek assurance and form confidence on six questions.
- Is the organisation ready to deploy this AI system?
- Has the Board seen enough qualified evidence to support the decision?
- Are accountabilities clear across supplier, provider, clinician, executive, and Board?
- Are clinical safety, information governance, cyber, equality, procurement, and risk controls joined up?
- Can the organisation monitor AI behaviour after deployment?
- Can the Board pause, challenge, escalate, or stop use when evidence changes?
AI readiness is not a certificate on a supplier register. NHS England’s Ambient Voice Technology registry supports procurement. Assurance and decision-making remain with each local NHS organisation.
Local responsibility is where Board confidence must be built.
AI does not behave like ordinary software.
Outputs vary. Model behaviour drifts. Errors look plausible. Bias hides in data, in workflow, in adoption patterns, in clinician trust. Automation bias can turn a support tool into a shadow decision-maker. Supplier assurance answers part of the question, never the whole.
A Board needs more than enthusiasm, procurement compliance, or digital maturity. A Board needs evidence that the organisation can govern the real use of AI.
That means evidence on
- lawful basis and transparency
- clinical safety risks identified and owned
- meaningful human review preserved
- information governance duties met
- cyber and supplier risk understood
- equality and bias actively considered
- post-deployment monitoring in place
- benefits and harms measured
- escalation and stop criteria defined
- learning captured and reported
NHS England guidance on AI-enabled ambient scribing sets out practical adoption requirements: clinical safety, workflow integration, supplier registry alignment, information governance, and local assurance activity.
The PRAXIA AI Readiness Diagnostic.
A practical Board assurance product. Not a generic maturity assessment.
The Diagnostic helps NHS Boards and executive teams establish whether the organisation is ready to deploy AI safely, lawfully, and effectively.
Built for Trust Boards, audit and quality committees, digital and transformation committees, executive teams, SIROs, Caldicott Guardians, CIOs, CCIOs, Medical Directors, Chief Nursing Officers, procurement and risk leads.
Ten domains of readiness.
- Board governance and authority.Who may approve, monitor, pause, escalate, or stop AI use? Are these powers visible in the Board and committee architecture?
- Strategic fit and value.Does proposed AI use serve lawful aims, patient benefit, workforce sustainability, productivity, or public value?
- Risk framework alignment.Are AI risks classified, owned, escalated, and linked to principal risks, operational risks, and risk appetite?
- Clinical safety.Are clinical hazards addressed? DCB0129 and DCB0160. Safety cases. Clinical Safety Officer responsibilities.
- Information governance.Lawful basis. Transparency. Privacy notices. DPIAs. Data flows. Retention. Patient rights. Caldicott. Professional duties.
- Cyber and infrastructure.Can the organisation support deployment through secure systems, access controls, integration, monitoring, resilience, and incident response?
- Supplier and procurement assurance.Has supplier evidence been reviewed beyond marketing claims? Safety, performance, data handling, liability, subcontractors, support.
- Human oversight and workflow.Does workflow design preserve professional judgement, or does it drift into passive approval, automation bias, and hidden workarounds?
- Equality, bias, and patient impact.Could AI use worsen inequity, exclude particular groups, or create uneven quality of care?
- Post-market surveillance and learning.Can the organisation monitor performance, incidents, near misses, errors, overrides, drift, benefits, harms, and lessons after deployment?
Outputs.
- AI Readiness Board Report
- AI Readiness Evidence Map
- AI Risk and Assurance Register
- Board decision checklist
- AI deployment control pathway
- Post-market surveillance model
- Board and committee reporting template
- Prioritised actions, weighted by risk and readiness gap
This is not a generic maturity assessment. It is a Board assurance entry-level prerequisite.
Four ways to engage.
A focused session for Boards, committees, or executive teams.
Outputs
- Tailored Board briefing
- Readiness overview
- Key scrutiny questions
- Recommended next steps
A structured assessment of organisational readiness across the ten domains.
Outputs
- Readiness assessment
- Evidence gap analysis
- Board report
- Prioritised action plan
A focused review for organisations considering, piloting, or scaling AI-enabled ambient scribing.
Outputs
- AVT assurance pack
- Local due diligence checklist
- IG and DPIA evidence map
- Clinical safety evidence map
- Human review and transparency controls
- Post-deployment monitoring plan
A practical model for monitoring AI use after approval.
Outputs
- Surveillance rhythm
- Incident and near-miss capture
- Performance and drift monitoring
- Benefits and harm tracking
- Board reporting template
- Escalation and stop criteria
AI readiness is not a technical checklist.
A digitally mature organisation may still be unready to govern AI. Board authority unclear. Risks fragmented. Evidence thin. Post-deployment monitoring absent. Human review hardened into ritual.
An organisation should not freeze because regulation is evolving. The task is to make adoption governable.
PRAXIA helps NHS Boards move from uncertainty to structured judgement.
Ten questions a Board should ask before approving AI.
- What problem are we solving, and why is AI the appropriate response?
- What evidence shows the product is safe, effective, lawful, and proportionate?
- What evidence shows our organisation is ready to use it safely?
- Who remains accountable when the output is wrong?
- How is professional judgement protected?
- How will patients know AI is in use?
- What data is processed, retained, transferred, or deleted?
- How is bias, exclusion, or unequal impact detected?
- What is monitored after deployment?
- What evidence would cause us to pause, restrict, or stop use?
Prepare before adoption outruns assurance.
PRAXIA.CH works with NHS Boards and executive teams to assess AI readiness, strengthen assurance, and build evidence for safe, lawful, and effective deployment.
